Celgene revenue was $15.28 b in FY, 2018 which is a 17.5% year over year increase from the previous period.
Founding Date | 1986 |
Celgene revenue breakdown by business segment: 10.5% from Inflammation & Immunology, 89.4% from Hematology / Oncology and 0.1% from Other
Celgene revenue breakdown by geographic segment: 34.4% from International and 65.6% from U.S.
USD | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|
Revenue | 11.2b | 13.0b | 15.3b |
Revenue growth, % | 21% | 16% | 18% |
Cost of goods sold | 438.0m | 461.0m | 587.0m |
Gross profit | 10.8b | 12.5b | 14.7b |
Gross profit Margin, % | 96% | 96% | 96% |
R&D expense | 4.5b | 5.9b | 5.7b |
General and administrative expense | 2.7b | 2.9b | 3.3b |
Operating expense total | 7.6b | 7.8b | 9.5b |
Depreciation and amortization | 459.0m | 329.0m | 468.0m |
EBIT | 3.2b | 4.7b | 5.2b |
EBIT margin, % | 28% | 36% | 34% |
Interest expense | 500.1m | 522.0m | 741.0m |
Pre tax profit | 2.4b | 4.3b | 4.8b |
Income tax expense | 373.3m | 1.4b | 786.0m |
Net Income | 2.0b | 2.9b | 4.0b |
EPS | 2.5 | 3.6 | 5.5 |
USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 3.0b | 3.3b | 3.3b | 3.5b | 3.8b | 3.9b | 4.0b | 4.4b | 4.5b |
Cost of goods sold | 113.0m | 111.0m | 118.0m | 135.0m | 126.0m | 157.0m | 140.0m | 151.0m | 167.0m |
Gross profit | 2.8b | 3.2b | 3.2b | 3.4b | 3.7b | 3.7b | 3.9b | 4.2b | 4.4b |
Gross profit Margin, % | 96% | 97% | 96% | 96% | 97% | 96% | 97% | 97% | 96% |
R&D expense | 995.0m | 835.0m | 1.3b | 2.2b | 1.3b | 1.1b | 1.2b | 1.1b | 1.2b |
General and administrative expense | 620.0m | 939.0m | 608.0m | 864.0m | 790.0m | 746.0m | 773.0m | 793.0m | 781.0m |
Operating expense total | 1.7b | 1.8b | 2.1b | 3.2b | 2.2b | 2.1b | 2.2b | 2.1b | 2.1b |
Depreciation and amortization | 82.0m | 88.0m | 80.0m | 87.0m | 127.0m | 127.0m | 109.0m | 109.0m | 109.0m |
EBIT | 1.1b | 1.3b | 1.1b | 218.0m | 1.5b | 1.7b | 1.7b | 2.1b | 2.3b |
EBIT margin, % | 38% | 40% | 33% | 6% | 39% | 43% | 42% | 48% | 50% |
Interest expense | 127.0m | 126.0m | 127.0m | 166.0m | 192.0m | 193.0m | 192.0m | 192.0m | 190.0m |
Pre tax profit | 1.0b | 1.1b | 991.0m | 1.0b | 1.3b | 1.4b | 1.8b | 1.8b | 1.9b |
Income tax expense | 84.0m | 69.0m | 3.0m | 184.0m | 262.0m | 296.0m | 269.0m | 250.0m | 226.0m |
Net Income | 941.0m | 1.1b | 988.0m | 846.0m | 1.0b | 1.1b | 1.5b | 1.6b | 1.7b |
EPS | 1.2 | 1.3 | 1.2 | 1.1 | 1.4 | 1.5 | 2.1 | 2.2 | 2.3 |
USD | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|
Cash | 6.2b | 7.0b | 4.2b |
Accounts Receivable | 1.6b | 1.9b | 2.1b |
Inventories | 497.9m | 541.0m | 458.0m |
Current Assets | 10.9b | 14.9b | 9.1b |
PP&E | 929.8m | 1.1b | 1.4b |
Goodwill | 4.9b | 4.9b | 8.0b |
Total Assets | 28.1b | 30.1b | 35.5b |
Accounts Payable | 247.1m | 305.0m | 418.0m |
Short-term debt | 500.7m | 501.0m | |
Current Liabilities | 3.0b | 3.0b | 4.1b |
Long-term debt | 137.9b | 15.8b | 19.8b |
Total Debt | 138.4b | 15.8b | 20.3b |
Total Liabilities | 21.5b | 23.2b | 29.3b |
Common Stock | 9.5m | 10.0m | 10.0m |
Preferred Stock | |||
Additional Paid-in Capital | 12.4b | 13.8b | 15.0b |
Retained Earnings | 10.1b | 13.1b | 17.6b |
Total Equity | 6.6b | 6.9b | 6.2b |
Debt to Equity Ratio | 21 x | 2.3 x | 3.3 x |
Debt to Assets Ratio | 4.9 x | 0.5 x | 0.6 x |
Financial Leverage | 4.3 x | 4.4 x | 5.8 x |
USD | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|
Net Income | 2.0b | 2.9b | 4.0b |
Depreciation and Amortization | 504.7m | 471.0m | 635.0m |
Accounts Receivable | (222.4m) | (236.0m) | (178.0m) |
Inventories | (55.3m) | (42.0m) | 82.0m |
Accounts Payable | 618.9m | 273.0m | 290.0m |
Cash From Operating Activities | 4.0b | 5.2b | 5.2b |
Purchases of PP&E | (236.2m) | (279.0m) | (330.0m) |
Cash From Investing Activities | (1.0b) | (2.9b) | (6.4b) |
Short-term Borrowings | (100.3m) | (5.7b) | |
Long-term Borrowings | (1.9b) | ||
Cash From Financing Activities | (1.6b) | (1.6b) | (1.5b) |
Net Change in Cash | 1.3b | 843.0m | (2.8b) |
Interest Paid | 527.2m | 539.0m | 689.0m |
Income Taxes Paid | 373.0m | 475.0m | 1.2b |
USD | FY, 2016 |
---|---|
Revenue/Employee | 1.6m |
Debt/Equity | 21 x |
Debt/Assets | 4.9 x |
Financial Leverage | 4.3 x |
FY, 2016 | FY, 2017 | FY, 2018 | |
---|---|---|---|
Active Clinical Studies | 52 | ||
Filed Trials Products (Acute Myeloid Leukemia) | 2 | 3 | 3 |
Filed Trials Products (Inflammation and Immunology) | 2 | 2 | 2 |
Filed Trials Products (Lymphoma) | 4 | 6 | 6 |
Filed Trials Products (Multiple Myeloma) | 4 | 5 | 5 |
Filed Trials Products (Myelodysplastic Syndromes) | 2 | 2 | 2 |
Filed Trials Products (Solid Tumors) | 4 | 4 | 4 |
Phase I Trials Products (Acute Myeloid Leukemia) | 3 | 2 | 3 |
Phase I Trials Products (Cellular Therapies) | 2 | ||
Phase I Trials Products (Chronic Lymphocytic Leukemia) | 2 | 1 | |
Phase I Trials Products (Inflammation and Immunology) | 3 | 3 | 3 |
Phase I Trials Products (Lymphoma) | 5 | 5 | 5 |
Phase I Trials Products (Multiple Myeloma) | 6 | 4 | 4 |
Phase I Trials Products (Myelodysplastic Syndromes) | 1 | 1 | |
Phase I Trials Products (Solid Tumors) | 4 | 5 | 3 |
Phase I/II Trials Products (Chronic Lymphocytic Leukemia) | 1 | 1 | |
Phase I/II Trials Products (Lymphoma) | 1 | 1 | |
Phase I/II Trials Products (Multiple Myeloma) | 1 | ||
Phase II Trials Products (Acute Myeloid Leukemia) | 1 | 1 | |
Phase II Trials Products (Cellular Therapies) | 2 | ||
Phase II Trials Products (Inflammation and Immunology) | 6 | 6 | 3 |
Phase II Trials Products (Multiple Myeloma) | 1 | 1 | |
Phase II Trials Products (Myelodysplastic Syndromes) | 2 | 2 | 1 |
Phase II Trials Products (Myelofibrosis) | 1 | 1 | |
Phase II Trials Products (Solid Tumors) | 3 | 3 | |
Phase III Trials Products (Acute Myeloid Leukemia) | 1 | 1 | 1 |
Phase III Trials Products (Beta Thalassemia) | 1 | 1 | 1 |
Phase III Trials Products (Inflammation and Immunology) | 5 | 2 | 4 |
Phase III Trials Products (Lymphoma) | 4 | 3 | 3 |
Phase III Trials Products (Myelodysplastic Syndromes) | 2 | 2 | 2 |
Phase III Trials Products (Solid Tumors) | 1 | 1 | 4 |